Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis

Company Overview

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Key Stats

• Today's Range: $6.76 to $6.76
• 50-Day Range: $6.76 to $6.76
• 52-Week Range: $2.06 to $7.01
• Volume: N/A
• Average Volume: 8.44 million shs
• Market Capitalization: $946.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACHN Stock Analysis - Frequently Asked Questions

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02.

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NEBLQ), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/07/2019
• Today: 7/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACHN
• CIK: 1070336
• Web: www.achillion.com
• Phone: 203-624-7000
• Fax: N/A
• Employees: 56
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.95%
• Return on Assets: -29.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.96
• Quick Ratio: 8.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.92 per share
• Price / Book: 3.52

Miscellaneous

• Outstanding Shares: 140,047,000
• Free Float: N/A
• Market Cap: $946.72 million
• Optionable: Optionable
• Beta: 1.59